References
- Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6.
- Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116. Academic Press Inc.
- Tuccori M, Ferraro S, Convertino I. et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. Internet]. 2020 [cited 2021 Feb 23];12:1854149.
- Focosi D, Anderson AO, Tang JW. et al. Convalescent plasma therapy for covid-19: state of the art [Internet]. Clin Microbiol Rev. American Society for Microbiology; 2020 [ cited 2021 Feb 24]. p. 1–17. Available from. https://pubmed.ncbi.nlm.nih.gov/32792417/
- Krammer F. SARS-CoV-2 vaccines in development [Internet]. Nature. Nat Res; 2020 [ cited 2021 Mar 22]. p. 516–527. Available from. 586.
- Convertino I, Tuccori M, Ferraro S. et al. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients [Internet]. Crit Care. BioMed Central Ltd; 2020 [ cited 2021 Apr 6]. p. 331. 24.
- Benton DJ, Wrobel AG, Xu P. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. Internet]. 2020 [cited 2021 Feb 16];588:327–330. Available from.
- Jones BE, Brown-Augsburger PL, Corbett KS. et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv Prepr Serv Biol. Internet]. 2020 [cited 2021 Feb 16]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33024963
- Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. Internet]. 2011 [cited 2021 Apr 22];477:466–470.
- Lynch RM, Boritz E, Coates EE, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. Internet]. 2015 [cited 2021 Apr 22];7:319ra206–319ra206.
- Rijal P, Elias SC, Machado SR, et al. Therapeutic monoclonal antibodies for ebola virus infection derived from vaccinated humans. Cell Rep. 2019;27:172–186.e7.
- Thornburg NJ, Zhang H, Bangaru S, et al. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J Clin Invest. Internet]. 2016 [cited 2021 Apr 22];126:1482–1494.
- Han HJ, Liu JW, Yu H, et al. Neutralizing monoclonal antibodies as promising therapeutics against middle east respiratory syndrome coronavirus infection [Internet]. Viruses. MDPI AG; 2018 [ cited 2021 Apr 22]. Available from
- Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med. 2002;96:S31–S35.
- Pollack P, Groothuis JR. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J. Infect. Chemother. Elsevier. 2002;8:201–206. .
- Lilly E, Phillips C, Advisor R. Emergency Use Authorization (EUA) for bamlanivimab 700mg IV Center for Drug Evaluation and Research (CDER) Review Identifying Information Application Type (EUA or Pre-EUA) If EUA, designate whether pre-event or intra-event EUA request. EUA EUA Application [Internet]. [cited 2021 Mar 10]. Available from. https://www.fda.gov/media/144118/download
- CHMP. Bamlanivimab and etesevimab for the treatment of COVID-19 (Eli Lilly) Art. 5 (3)- AR for publication [Internet]. 2021 [cited 2021 Apr 22]. Available from: https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-limited-antibody-combination-bamlanivimab/etesevimab-covid19-article-53-procedure-assessment-report_en.pdf.
- Hoffmann M, Arora P, Groß R. et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: escape from therapeutic 1 antibodies and antibodies induced by infection and vaccination 2 3. bioRxiv. Internet]. 2021 [cited 2021 Apr 26];2021.02.11.430787. Available from. . https://doi.org/10.1101/2021.02.11.430787
- Liu H, Wei P, Zhang Q. et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. bioRxiv Prepr Serv Biol. Internet]. 2021 [cited 2021 Apr 26]; Available from. http://www.ncbi.nlm.nih.gov/pubmed/33619479
- Wang P, Wang M, Yu J. et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv Prepr Serv Biol. Internet]. 2021 [cited 2021 Apr 26]; Available from. http://www.ncbi.nlm.nih.gov/pubmed/33688656
- Widera M, Wilhelm A, Hoehl S. et al. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv. Internet]. 2021 [cited 2021 Apr 26];2021.02.24.21252372. Available from… . . https://doi.org/10.1101/2021.02.24.21252372
- Widera M, Wilhelm A, Hoehl S, et al. Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro. J Infect Dis. 2021 Jul 5:jiab355. https://doi.org/10.1093/infdis/jiab355.Onlineaheadofprint.
- Starr TN, Greaney AJ, Dingens AS. et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell reports Med [Internet]. 2021 [cited 2021 Apr 26];2:100255.
- McCallum M, Bassi J, De Marco A. et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv. Internet]. 2021 [cited 2021 Apr 26];2021.03.31.437925. Available from. https://doi.org/10.1101/2021.03.31.437925
- Zhou H, Dcosta BM, Samanovic MI, et al. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv Prepr Serv Biol. 2021 Internet]. [cited 2021 Apr 26]; Available from; . http://www.ncbi.nlm.nih.gov/pubmed/33791698
- Focosi D, Tuccori M, Baj A, et al. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies. Viruses. Switzerland; 2021.
- Laiton-Donato K, Usme-Ciro JA, Franco-Muñoz C. et al. Title: novel highly divergent SARS-CoV-2 lineage with the Spike substitutions L249S and E484K. medRxiv. Internet]. 2021 [cited 2021 Apr 26];2021.03.12.21253000. Available from… . . https://doi.org/10.1101/2021.03.12.21253000
- Greaney AJ, Starr TN, Barnes CO, et al. Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. bioRxiv Prepr. Serv. Biol. 2021 Mar 18:2021.03.17.435863. doi: https://doi.org/10.1101/2021.03.17.435863.
- Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Internet]. Nat Rev Immunol. 2021 [cited 2021 Apr 29];1–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33875867
- Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 [Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04603651
- A study of LY3819253 (LY-CoV555) in healthy participants. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04537910
- Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) [Internet]. ClinicalTrials.gov. [cited 2021 Apr 13]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT04790240?term=bamlanivimab&draw=3&rank=14
- Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting [Internet]. ClinicalTrials.gov. [ cited 2021 Jul 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT04840459?term=bamlanivimab&draw=2&rank=6
- At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04656691
- A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19) [Internet]. ClinicalTrials.gov. cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04701658
- Treatment of Nosocomial COVID-19 (CATCO-NOS) Internet]. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04748588?term=bamlanivimab&draw=3&rank=4
- Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU (‘Autorisation Temporaire d’Utilisation’). A Prospectvie Cohort. [Internet]. ClinicalTrials.gov. [ cited 2021 Jul 7]. Available from…: https://clinicaltrials.gov/ct2/show/NCT04885452?term=bamlanivimab&draw=3&rank=14
- A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04411628
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness - BLAZE 4. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04634409?term=NCT04634409&draw=2&rank=1
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff [Internet] cited 2021 Apr 7]. Available from: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04497987?term=NCT04497987&draw=2&rank=1
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04427501?term=NCT04427501&draw=2&rank=1
- ACTIV-2: a Study for Outpatients With COVID-19. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04518410?term=NCT04518410&draw=2&rank=1
- ACTIV-3: therapeutics for Inpatients With COVID-19. Internet]. ClinicalTrials.gov. [cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04501978?term=NCT04501978&draw=2&rank=1
- A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19. [Internet]. ClinicalTrials.gov. [ cited 2021 Apr 7]. Available from…: https://clinicaltrials.gov/ct2/show/NCT04796402?term=NCT04796402&draw=2&rank=1
- Evaluation of Monoclonal Antibodies in COVID-19. [Internet]. ClinicalTrials.gov. [ cited 2021 Apr 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04790786?term=NCT04790786&draw=2&rank=1
- Gottlieb RL, Nirula A, Chen P. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA. Internet. 2021;325:632.
- ACTIV-3/TICO LY-CoV555 Study Group. et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. Internet]. 2021 [cited 2021 Apr 7];384:905–914.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383:1813–1826.
- Cohen MS, Nirula A, Mulligan MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. J Am Med Assoc. 2021;46225:46–55.
- Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 | FDA [Internet]. [cited 2021 Apr 7]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19.
- EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19 | European Medicines Agency. Internet]. [cited 2021 Apr 7]. Available from: https://www.ema.europa.eu/en/news/ema-starts-rolling-review-eli-lilly-antibodies-bamlanivimab-etesevimab-covid-19
- Webb BJ, Buckel W, Vento T. et al. Real-world effectiveness and tolerability of monoclonal antibodies for ambulatory patients with early COVID-19. medRxiv. Internet]. 2021 [cited 2021 Apr 7];2021.03.15.21253646. Available from…: https://doi.org/10.1101/2021.03.15.21253646
- Rainwater-Lovett K, Redd JT, Stewart MA. et al. Title: real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse 1 population in the United States 2 3. medRxiv. Internet]. 2021 [cited 2021 Apr 26];2021.04.08.21254705. Available from…: https://doi.org/10.1101/2021.04.08.21254705
- Jarrett M, Licht WB, Bock K. et al. Early experience with neutralizing monoclonal antibody therapy For COVID-19. medRxiv. Internet]. 2021 [cited 2021 Apr 26];2021.04.09.21255219. Available from: https://doi.org/10.1101/2021.04.09.21255219
- Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection. Open Forum Infect Dis. 8 Internet. 2021; Available from…: https://doi.org/10.1093/ofid/ofab254.
- Ganesh R, Pawlowski C, O’Horo JC, et al. Association of intravenous bamlanivimab use with reduced hospitalization, intensive care unit admission, and mortality in patients with mild to moderate COVID-19. medRxiv Prepr. Serv. Heal. Sci. 2021 May 25;2021.05.23.21257670. doi: https://doi.org/10.1101/2021.05.23.21257670.
- Wafa IA, Pratama NR, Budi DS, et al. The efficacy and safety of monoclonal antibody treatments against COVID-19: a systematic review and meta-analysis of randomized clinical trials. medRxiv. 2021 Internet. ;2021.06.04.21258343. Available from: http://medrxiv.org/content/early/2021/06/07/2021.06.04.21258343.abstract
- FDA Adverse Event Reporting System (FAERS) Public Dashboard | FDA [Internet]. [cited 2021 Jul 15]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.
- Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med Internet]. 2021;384:229–237.
- Moruf A. Fact sheet for health care providers Emergency Use Authorization (EUA) of bamlanivimab authorized use [Internet]. [cited 2021 Jul 15]. Available from: https://www.cdc.gov/growthcharts/clinical_charts.htm.
- U.S. Department of Health and Human Services. Update on COVID-19 variants and impact on bamlanivimab distribution [Internet]. [ cited 2021 Jul 15]. Available from: https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab/Pages/default.aspx.
- Gormley A. Bamlanivimab and Etesevimab EUA Letter of Authorization February 25. 2021.
- Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab | FDA. Internet]. [cited 2021 Apr 22]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab
- Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19 | GSK [Internet]. [cited 2021 Apr 26]. Available from: https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19/
- The COVID-19 treatment guidelines panel’s statement on the emergency use authorizations of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 [Internet]. Natl. Inst. Heal. - COVID-19 Guidel. 2021 [cited 2021 Jul 22]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-anti-sars-cov-2-monoclonal-antibodies-eua/
- AZD7442 - a potential combination therapy for the prevention and treatment of COVID-19. Internet]. ClinicalTrials.gov. [cited 2021 Apr 26]. Available from…: https://clinicaltrials.gov/ct2/show/NCT04507256?term=AZD7442&cond=COVID-19&draw=2&rank=4
- Phase III double-blind, placebo-controlled study of AZD7442 for pre-exposure prophylaxis of COVID-19 in adult. Internet]. ClinicalTrials.gov. [cited 2021 Apr 26]. Available from…: https://clinicaltrials.gov/ct2/show/NCT04625725?term=AZD7442&cond=COVID-19&draw=2&rank=3
- RU anti-SARS-CoV-2 (COVID-19) mAbs in healthy volunteers. Internet]. ClinicalTrials.gov. [cited 2021 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT04700163?term=c135%2C+c144&cond=COVID-19&draw=2&rank=1
- AGILE (Early Phase Platform Trial for COVID-19) [Internet] [ cited 2021 Apr 26]. Available from: ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04746183?term=VIR-7831&cond=COVID-19&draw=2&rank=4
- Focosi D, Franchini M. COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. Internet]. 2021 [cited 2021 Apr 29]; Available from: https://onlinelibrary.wiley.com/doi/epdf/https://doi.org/10.1111/vox.13091
- Focosi D, Novazzi F, Genoni A, et al. Emergence of SARS-CoV-2 Spike Escape Mutation Q493R After Bamlanivimab/Etesevimab Treatment for COVID-19 [Internet]. Res. Sq. 2021. p. 3–6. Available from: https://www.researchsquare.com/article/rs-524959/v1
- Borrok MJ, DiGiandomenico A, Beyaz N, et al. Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies. JCI Insight. Internet]. 2018 [cited 2021 Apr 26];3.